leadership position for clinical development of therapeutics for CD36-mediated diseases.http://mperiathera.com We carefully have developed a series of potent, short-chain peptides for high specificity binding of the CD36 receptor, to promote the best therapeutic of all, the patient’s own innate immune system.

Comments

Who Upvoted this Story